'Edwards Lifesciences' TAVR Boom Drives Q1 Performance Surge and Guidance Upgrade

Edwards Lifesciences Corp. (EW) reported first-quarter results for the period ended March 31, 2026, with revenue of $1.65 billion—a 16.7% increase year-over-year—and adjusted earnings per share of $0.78. The company attributed the strong performance to double-digit growth in its TAVR and TMTT businesses and consequently raised its full-year revenue and EPS growth guidance.

Based on these results, Edwards lifted its annual TAVR revenue growth target to 7–9% and completed a $500 million accelerated share repurchase. At quarter-end, it held $2.4 billion in cash and cash equivalents and $0.6 billion in total debt (approximately KRW 3.2 trillion and KRW 0.8 trillion, respectively).

On April 2, Senior Vice President of Strategy and Corporate Development Donald E. Bobo Jr. exercised 22,680 stock options and sold all shares in the open market, realizing about $1.82 million (roughly KRW 2.5 billion) in proceeds. He still retains a substantial stake through direct and indirect holdings.

At the recent American Heart Association annual meeting, Edwards presented two-year follow-up data from the TRISCEND II trial of its EVOQUE transcatheter tricuspid valve replacement system, showing sustained symptom improvement and risk reduction in patients with tricuspid valve disease, further expanding its structural heart disease portfolio.

In March, Chief Financial Officer Scott Ullem purchased 13,000 shares on the open market—an insider buy valued at approximately $770,000 (about KRW 1 billion).

Headquartered in Irvine, California, Edwards Lifesciences is a medical device company focused on structural heart disease therapies, including replacement heart valves, cardiovascular monitoring equipment, and the SAPIEN TAVR platform. The company has built a broad portfolio spanning TAVR, transcatheter mitral and tricuspid interventions, and surgical structural heart procedures, and at its annual investor conference reaffirmed its strategy to drive growth beyond 2026 through continued R&D investment and clinical data generation.